Outsmart your patient’s lung cancer

Predict and prevent recurrence in patients with early-stage NSCLC with RiskReveal™

What is RiskReveal?

Test Overview

RiskReveal is a molecular stratification test to identify patients with IA-IIA non-squamous non-small cell lung cancer (NSCLC) who may be at low- or high-risk of having a recurrence.

RiskReveal is appropriate for all patients with stage IA, IB or IIA non-squamous NSCLC who have undergone surgical resection and are now being considered for chemotherapy in the next stage of their care.

How It Works

RiskReveal testing can be performed on any NSCLC that has been resected. You’ll need to send tumor tissue to Razor Genomics’ lab, where the molecular signature is analyzed to stratify your patient’s risk. The result comes back in time to facilitate post-operative discussion with patients about the potential benefit of adjuvant treatment.

Data

RiskReveal has been validated in two independent cohorts with close to 1400 patients and outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIB non-squamous NSCLC (1).
In a single institution prospective study, patients identified by RiskReveal as high-risk and who were treated with adjuvant chemotherapy had 91.7% 5-year disease-free survival compared to 48.9% 5-year DFS for high-risk patients who did not receive chemotherapy (2). In a study of physician practices, RiskReveal results led to a change in treatment recommendation for 30% of patients (3).

You can now identify which early-stage patients can benefit from chemotherapy

Roughly 40,000 patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year (4). 30-50% of early-stage patients will die within five years of their operation, despite complete surgical resection.

As a surgeon, there’s nothing worse than telling your patient their cancer has returned – especially when recurrence can be mitigated through adjuvant chemotherapy.

The NCCN recommends chemotherapy for patients with stage IA-IIA NSCLC who are at a high risk for recurrence after resection, but does not provide validated criteria for identifying these high-risk patients.

The first and only test of its kind, RiskReveal now offers clinicians a clear indication of which patients may be likely to benefit from adjuvant chemotherapy. RiskReveal is the molecular testing solution in early-stage NSCLC, guiding treatment selection of adjuvant chemotherapy. This leads to more confident treatment decisions for all of your stage IA-IIA patients.

“I think that RiskReveal is practice-changing and very important for discussions that we have with patients. I like giving patients enough information about their situation, and the pros and cons of additional treatment after their operation, so they’re loaded with the information to help them decide if they want adjuvant treatment.”

Robert McKenna, MD

Thoracic Surgeon, John Wayne Cancer Institute

Good for your patients

Good for your practice

A Pioneer in Precision Treatment

RiskReveal offers insight into the best possible treatment decisions for your patients and may minimize the risk of under-treating patients who could benefit from chemotherapy and overtreating those for whom surgery is likely curative.

Becoming an early adopter of this innovative predictive test can improve your confidence in patient care and continuity of management.

RiskReveal is paving the way for improved stage IA-IIA NSCLC outcomes, giving surgeons a way to accurately assess the level of recurrence risk and identify the next steps for their patients.

FAQs

  • RiskReveal is a 14-gene molecular treatment stratification test to identify patients with Stage IA, IB and IIA non-squamous NSCLC who may be at low- or high-risk of having a recurrence and likely benefit from adjuvant chemotherapy.

  • RiskReveal is appropriate for all patients with Stage IA, IB or IIA non-squamous non-small cell lung cancer (NSCLC) who have undergone surgical resection and are now being considered for adjuvant treatment in the next stage of their care.

  • Results classify patients into low, intermediate, or high-risk of disease recurrence. In a non-randomized, prospective study of 250 patients who were surgically resected at a single institution, patients in the high- and intermediate-risk categories who were treated with adjuvant chemotherapy had significantly better survival than high- and intermediate-risk patients who did not receive chemotherapy.

  • RiskReveal has been clinically validated in two independent cohorts with close to 1400 patients (Kratz et al, Lancet, 2012).

    A prospective study found that test-identified high/intermediate risk patients who were treated with adjuvant platinum-based chemotherapy had 91.7% 5-year disease-free survival (DFS) compared to 48.9% 5-year DFS for high/intermediate risk patients who did not receive chemotherapy. RiskReveal-identified low-risk patients had a disease-free survival (DFS) of 93.8% without adjuvant chemotherapy (Woodard GA, et al. Clinical Lung Cancer, 2018).

    The significant difference in survival between treated vs. untreated high/intermediate-risk patients was reinforced in an expanded 250-patient prospective cohort, in which most patients were stage IA (Woodard GA, et al. Clin Lung Cancer, 2021).

    See a complete list of publications for more information

  • Contact us at 1-844-662-6298 or cs@razorgenomics.com to set up an account.

    You may then order the RiskReveal test, track testing progress and access test results in your physician portal.

  • Razor Genomics will provide a FFPE tissue shipping kit with detailed sample preparation and shipping instructions. We accept a tissue block or slides.

  • Results are typically ready within 10 business days from the time we receive the specimen.

  • We accept all forms of insurance including Medicare. Medicare covers the RiskReveal test, but we are currently out of network with other insurances. Once we have completed a patient’s test, we send them a letter explaining our insurance and financial assistance process. Patients who would like to be pre-qualified for financial assistance, or have any questions regarding insurance billing, can contact us at 1-844-662-6298.

References
1. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
2. Dormady, et al. (2015) The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol 20:59..
3. Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58
4. SEER data.